Compare DSX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSX | AARD |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.7M | 281.1M |
| IPO Year | N/A | N/A |
| Metric | DSX | AARD |
|---|---|---|
| Price | $2.48 | $3.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $19.63 |
| AVG Volume (30 Days) | ★ 931.3K | 447.4K |
| Earning Date | 02-26-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.28 | N/A |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $4.06 |
| 52 Week High | $2.72 | $17.94 |
| Indicator | DSX | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 19.79 |
| Support Level | $2.26 | N/A |
| Resistance Level | $2.72 | $6.19 |
| Average True Range (ATR) | 0.13 | 0.45 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 54.32 | 2.94 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation, the services provided by the vessels are similar and all operate under the same economic environment.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.